Cellectar Biosciences Inc... (CLRB)
| Bid | 0.29 |
| Market Cap | 13.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.4 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | -0.38 |
| Analyst | Buy |
| Ask | 0.3 |
| Volume | 593,055 |
| Avg. Volume (20D) | 1,679,863 |
| Open | 0.30 |
| Previous Close | 0.30 |
| Day's Range | 0.29 - 0.31 |
| 52-Week Range | 0.22 - 4.15 |
| Beta | 0.96 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...
Analyst Forecast
According to 2 analyst ratings, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 9505.49% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptCellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and ...